These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 15140913)

  • 1. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
    De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
    J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat.
    De Vry J; Jentzsch KR
    Eur J Pharmacol; 2004 Nov; 505(1-3):127-33. PubMed ID: 15556145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
    Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
    Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
    J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis.
    Gutierrez T; Farthing JN; Zvonok AM; Makriyannis A; Hohmann AG
    Br J Pharmacol; 2007 Jan; 150(2):153-63. PubMed ID: 17160008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
    Sain NM; Liang A; Kane SA; Urban MO
    Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin.
    Hohmann AG; Farthing JN; Zvonok AM; Makriyannis A
    J Pharmacol Exp Ther; 2004 Feb; 308(2):446-53. PubMed ID: 14610224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties.
    Mauler F; Mittendorf J; Horváth E; De Vry J
    J Pharmacol Exp Ther; 2002 Jul; 302(1):359-68. PubMed ID: 12065738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic cannabinoids produce CB₁-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors.
    Seyrek M; Kahraman S; Deveci MS; Yesilyurt O; Dogrul A
    Eur J Pharmacol; 2010 Dec; 649(1-3):183-94. PubMed ID: 20868676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo.
    Lunn CA; Fine JS; Rojas-Triana A; Jackson JV; Fan X; Kung TT; Gonsiorek W; Schwarz MA; Lavey B; Kozlowski JA; Narula SK; Lundell DJ; Hipkin RW; Bober LA
    J Pharmacol Exp Ther; 2006 Feb; 316(2):780-8. PubMed ID: 16258021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
    McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
    Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
    Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
    J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.
    Wilkinson JD; Williamson EM
    J Dermatol Sci; 2007 Feb; 45(2):87-92. PubMed ID: 17157480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.
    LaBuda CJ; Koblish M; Little PJ
    Eur J Pharmacol; 2005 Dec; 527(1-3):172-4. PubMed ID: 16316653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
    Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
    J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
    Honore P; Wismer CT; Mikusa J; Zhu CZ; Zhong C; Gauvin DM; Gomtsyan A; El Kouhen R; Lee CH; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
    J Pharmacol Exp Ther; 2005 Jul; 314(1):410-21. PubMed ID: 15837818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid agonists induce contractile responses through Gi/o-dependent activation of phospholipase C in the bovine ciliary muscle.
    Lograno MD; Romano MR
    Eur J Pharmacol; 2004 Jun; 494(1):55-62. PubMed ID: 15194451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
    Deng L; Cornett BL; Mackie K; Hohmann AG
    Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
    Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.